{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:50:26Z","timestamp":1780044626650,"version":"3.53.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ESCMID\/FEMS research fellowship"},{"DOI":"10.13039\/501100022335","name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PI14\/00603"],"award-info":[{"award-number":["PI14\/00603"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["20152610"],"award-info":[{"award-number":["20152610"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"La Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Network for Research in Infectious Diseases","award":["REIPI RD06\/0008"],"award-info":[{"award-number":["REIPI RD06\/0008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Traditional treatment of methicillin-susceptible Staphylococcus aureus (MSSA) native valve endocarditis is based on cloxacillin\/cefazolin monotherapy. Antibiotics with high activity against MSSA, such as ceftaroline and daptomycin, have been marketed for years, but there are no clinical trials evaluating them as monotherapy or combination therapy in patients with MSSA endocarditis. The objective of this study was to compare the efficacy of cloxacillin, ceftaroline, and daptomycin monotherapies and daptomycin combinations with \u03b2-lactams in a rabbit model of MSSA endocarditis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Endocarditis was induced in rabbits with 2 strains of MSSA. After 24 hours of infection, they received human-like doses of cloxacillin, ceftaroline, or daptomycin or combinations of daptomycin plus either cloxacillin or ceftaroline. Isolates recovered from vegetation, spleen, and kidney were retested for daptomycin nonsusceptibility (DNS) posttreatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MSSA vancomycin minimum inhibitory concentration did not influence the efficacy of any antibiotic treatment. Cloxacillin, ceftaroline, and daptomycin had similar activity (25%\u201350%) in sterilizing vegetations. However, 13% of rabbits treated with daptomycin developed DNS. The addition of daptomycin to cloxacillin or ceftaroline was synergistic and bactericidal, showing significantly more activity and higher rates of sterile vegetations (\u226590%) than any monotherapy. Combinations also showed better activity in spleens and kidneys as compared with daptomycin monotherapy and prevented the development of DNS in all tissues. There were no differences between the daptomycin combinations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the MSSA experimental endocarditis model, daptomycin combinations with \u03b2-lactams had significantly better activity than any of the monotherapies in sterilizing valve vegetations and preventing DNS development. These findings support their use in clinical practice and to perform clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf245","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T03:00:21Z","timestamp":1746673221000},"page":"540-549","source":"Crossref","is-referenced-by-count":6,"title":["Time to Reappraise the Antibiotic Treatment for Methicillin-Susceptible <i>Staphylococcus aureus<\/i> Infective Endocarditis: Data From the Experimental Model"],"prefix":"10.1093","volume":"232","author":[{"given":"Cristina","family":"Garc\u00eda-de-la-M\u00e0ria","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-458X","authenticated-orcid":false,"given":"Oriol","family":"Gasch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona , Sabadell ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A","family":"Ca\u00f1as-Pacheco","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Marco","sequence":"additional","affiliation":[{"name":"Microbiology Service and ISGlobal, Hospital Clinic\u2013University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-1127","authenticated-orcid":false,"given":"Marta","family":"Hern\u00e1ndez-Meneses","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Quintana","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC. Instituto de Salud, Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Falces","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Tolosana","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Vidal","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Pericas","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Perissinotti","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Llopis","sequence":"additional","affiliation":[{"name":"Department of Statistics, Faculty of Biology, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC. Instituto de Salud, Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-7755","authenticated-orcid":false,"given":"Jos\u00e9 M","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic of Barcelona-IDIBAPS, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC. Instituto de Salud, Carlos III , Madrid ,","place":["Spain"]},{"name":"Reial Academia de Medicina de Catalunya , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025092306164691900_jiaf245-B1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/431979","article-title":"Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis merged database","volume":"41","author":"Miro","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archinternmed.2008.603","article-title":"Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis\u2013Prospective Cohort Study","volume":"169","author":"Murdoch","year":"2009","journal-title":"Arch Intern Med"},{"key":"2025092306164691900_jiaf245-B3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.1989.03420100107033","article-title":"Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci","volume":"261","author":"Bisno","year":"1989","journal-title":"JAMA"},{"key":"2025092306164691900_jiaf245-B4","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1161\/CIRCULATIONAHA.105.165563","article-title":"Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"key":"2025092306164691900_jiaf245-B5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/AAC.6.6.802","article-title":"Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides","volume":"6","author":"Watanakunakorm","year":"1974","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2025092306164691900_jiaf245-B6","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijantimicag.2010.11.006","article-title":"Aminoglycoside-containing antibiotic combinations for the treatment of bacterial endocarditis: an evidence-based approach","volume":"36","author":"Leibovici","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2025092306164691900_jiaf245-B7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2025092306164691900_jiaf245-B9","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis: developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092306164691900_jiaf245-B10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","article-title":"Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users","volume":"34","author":"Small","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025092306164691900_jiaf245-B12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cid\/ciu183","article-title":"Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis","volume":"58","author":"Cervera","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/cid\/cir858","article-title":"An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"54","author":"Miller","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B14","doi-asserted-by":"crossref","first-page":"e01579","DOI":"10.1128\/AAC.01579-19","article-title":"Relationship between vancomycin MIC and virulence gene expression in clonal complexes of methicillin-susceptible Staphylococcus aureus strains isolated from left-sided endocarditis","volume":"64","author":"Peric\u00e0s","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cmi.2017.01.017","article-title":"Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal \u03b2-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis","volume":"23","author":"Peric\u00e0s","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2025092306164691900_jiaf245-B16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2025092306164691900_jiaf245-B17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkt396","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin","volume":"69","author":"Gasch","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025092306164691900_jiaf245-B18","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00051-09","article-title":"Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin- resistant Staphylococcus aureus","volume":"53","author":"Mir\u00f3","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B19","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1093\/jac\/dkaa354","article-title":"Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis","volume":"75","author":"Garc\u00eda-De-La-M\u00e0ria","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025092306164691900_jiaf245-B20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2025092306164691900_jiaf245-B21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal \u03b2-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2146\/ajhp160006","article-title":"Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"74","author":"White","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"2025092306164691900_jiaf245-B24","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jac\/dkz253","article-title":"Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report","volume":"74","author":"Duss","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025092306164691900_jiaf245-B25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/jcm10081743","article-title":"New-generation antibiotics for treatment of gram-positive infections: a review with focus on endocarditis and osteomyelitis","volume":"10","author":"Bloem","year":"2021","journal-title":"J Clin Med"},{"key":"2025092306164691900_jiaf245-B26","volume-title":"Performance standards for antimicrobial susceptibility testing; 27th informational supplement. CLSI document M100","author":"Clinical Laboratory Standards Institute","year":"2017"},{"key":"2025092306164691900_jiaf245-B27","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.00510-07","article-title":"Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus","volume":"52","author":"Marco","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/AAC.46.2.378-384.2002","article-title":"Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis","volume":"46","author":"Gavald\u00e0","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B29","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B30","doi-asserted-by":"crossref","first-page":"e02633","DOI":"10.1128\/AAC.02633-17","article-title":"The combination of daptomycin and fosfomycin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant Staphylococcus aureus in a rabbit model of experimental endocarditis","volume":"62","author":"Garc\u00eda-de-la-M\u00e0ria","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B31","first-page":"231","volume-title":"Antibiotics in laboratory medicine","author":"Edberg","year":"1996"},{"key":"2025092306164691900_jiaf245-B32","first-page":"394","article-title":"Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart","volume":"42","author":"Garrison","year":"1970","journal-title":"Yale J Biol Med"},{"key":"2025092306164691900_jiaf245-B33","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025092306164691900_jiaf245-B34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","article-title":"Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus","volume":"92","author":"Sakoulas","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"2025092306164691900_jiaf245-B35","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1128\/AAC.00799-13","article-title":"Daptomycin in vitro activity against methicillin-resistant Staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge","volume":"57","author":"Gasch","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B36","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025092306164691900_jiaf245-B37","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025092306164691900_jiaf245-B38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025092306164691900_jiaf245-B39","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025092306164691900_jiaf245-B40","doi-asserted-by":"crossref","first-page":"e023151","DOI":"10.1136\/bmjopen-2018-023151","article-title":"Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial","volume":"8","author":"Burdet","year":"2018","journal-title":"BMJ Open"},{"key":"2025092306164691900_jiaf245-B41","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/cid\/ciz018","article-title":"Impact of \u03b2-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis","volume":"69","author":"Grillo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B42","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz746","article-title":"Daptomycin plus \u03b2-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","volume":"71","author":"Jorgensen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025092306164691900_jiaf245-B44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Australasian Society for Infectious Diseases Clinical Research Network. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2025092306164691900_jiaf245-B45","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B46","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306164691900_jiaf245-B47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2024.11.022","article-title":"Ceftaroline MRSA Group Spain GEIRAS-SEIMC. Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study","volume":"31","author":"Villa","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2025092306164691900_jiaf245-B48","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"2025092306164691900_jiaf245-B49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025092306164691900_jiaf245-B50","doi-asserted-by":"crossref","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf245\/63105378\/jiaf245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/540\/63105378\/jiaf245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/540\/63105378\/jiaf245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:19:25Z","timestamp":1758622765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/3\/540\/8126787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf245","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,5,8]]}}}